Activaero Cooperates with Bayer HealthCare in the Development of Inhaled Treatments
Bayer licenses rights to Activaero's pulmonary delivery platform
Activaero GmbH announced a licensing and option agreement with Bayer HealthCare AG on the development of inhaled treatments. Under the terms of the agreement, Activaero will receive an upfront payment and in case the option will be exerted subsequently milestone payments as well.
Dr. Gerhard Scheuch, Founder and CEO of Activaero commented: "This licensing deal represents a major milestone for Activaero and together with our scientific team, we look forward to supporting Bayer HealthCare throughout the upcoming development. We believe that pulmonary administration of drugs has a huge potential for the treatment of lung diseases and diseases which start in the lung. With this in mind, it will be exciting to develop innovative therapies with Bayer HealthCare, a world-wide leader in the pharmaceutical business for decades."
Activaero has been supported in the strategy, negotiation and process of this licensing transaction by Tytonis B.V.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.